🔬 New publication
Long-term follow-up and high-quality biospecimens from clinical trials provide a unique foundation for translational cancer research.
A new study highlights the value of samples from #ABCSG-8 in advancing biomarker research in early breast cancer.
1
107
The study validated the prognostic performance of the Xpert Breast Cancer Insight (BC Insight) Test in ER-positive, HER2-negative early breast cancer.
The test was shown to predict distant recurrence and overall survival, supporting biomarker-based risk assessment.
1
47
This publication demonstrates how well-characterized clinical trial cohorts continue to generate scientific insights beyond their original objectives – contributing to the advancement of precision oncology.
📖 doi.org/10.1016/j.clbc.2026.…
#TranslationalResearch #PrecisionOncology
17
📘 #ABCSG Annual Report 2025 is now online!
A highly productive year for the ABCSG is now summarized in our new Annual Report. 🔬
👉 Full report: abcsg.org/wp/wp-content/uplo…
1
52
The Annual Report also highlights key developments in:
▪️ Clinical research
▪️ Translational projects
▪️ International collaborations
▪️ Education & training activities
1
20
We sincerely thank all investigators, study nurses and study coordinators, patients, and team members of the trial office for their continued commitment. 🤝
👉 Full report: abcsg.org/wp/wp-content/uplo…
35
🌍 How can we balance global standards with regional realities in breast cancer care?
A new editorial by #ABCSG President @MichaelGnant Gnant explores this key question:
👉 doi.org/10.20892/j.issn.2095…
1
48
Clinical research, precision medicine & AI are rapidly transforming care - but how can these advances be implemented across diverse healthcare systems while accounting for clinical heterogeneity?
1
11
💬 “Our goal must be to align global standards with regional realities in order to ensure the best possible care for all patients.” so @MichaelGnant
#ABCSGbefirst #BreastCancer #CancerResearch #ClinicalTrials #Oncology #PrecisionMedicine #GlobalHealth 🧬
15
🎉 New #ABCSG publication (article in press)!
📖 Long-term prognostic value of ctDNA in early breast cancer
Insights from the ABCSG-34 trial
Egle D. et al., npj Breast Cancer (2026)
🔗 doi.org/10.1038/s41523-026-0…
#BreastCancer #Oncology #ABCSGbefirst
1
128
🔬 Long-term follow-up from #ABCSG-34 shows:
Baseline ctDNA positivity in early breast cancer is associated with less favorable survival outcomes.
➡️ Supporting ctDNA as a prognostic biomarker
#ctDNA #Biomarkers #CancerResearch
1
44
🧪 Findings also highlight:
• Potential of ctDNA monitoring during neoadjuvant therapy
• Importance of long-term translational research
👏 Thanks to all investigators & collaborators!
#TranslationalResearch #ClinicalTrials #NeoadjuvantTherapy
15
Important guidance for #BreastCancer in the context of the Austrian treatment landscape 🇦🇹
New publication in #WienerKlinischeWochenschrift:
👉 “Austrian treatment algorithms 2025: CDK4/6 inhibitors in the adjuvant therapy of HR+/HER2– early breast cancer”
@MichaelGnant
1
60
🔗doi.org/10.1007/s00508-026-0…
Authored by leading #ABCSG investigators, this publication provides orientation in a changing therapeutic landscape and supports informed treatment decisions in clinical practice.
#EarlyBreastCancer #Oncology #CancerResearch #AdjuvantTherapy
44
#CancerWorld magazine features @MichaelGnant, President of the Austrian Breast & Colorectal Cancer Study Group #ABCSG.
📖 Issue 113 (03/2026)
🔗 abcsg.org/wp/wp-content/uplo…
The profile highlights his work challenging overtreatment, advancing international clinical trials, and shaping the future of oncology - a thoughtful portrait of a physician-scientist challenging established routines.
#ABCSGbefirst #BreastCancer #Oncology #ClinicalTrials
1
37

